

美国 CDC 发布人类环境化学物接触水平的研究报告(二)

徐甫, 刘萍 编译; 邬春华, 周志俊* 审校

续表

Metals 金属

- Antimony 锑
- Arsenic, Total 砷, 总砷
- Arsenic(V) acid 砷酸(V)
- Arsenobetaine 砷甜菜碱
- Arsenocholine 砷胆碱
- Arsenous(III) acid 亚砷酸(III)
- Dimethylarsinic acid 二甲基砷酸
- Monomethylarsonic acid 甲基砷酸
- Trimethylarsine oxide 三甲基氧化砷
- Barium 钡
- Beryllium 铍
- Cadmium 镉
- Cesium 铯
- Cobalt 钴
- Lead 铅
- Mercury 汞
- Molybdenum 钼
- Platinum 铂
- Thallium 铊
- Tungsten 钨
- Uranium 铀

Perfluorochemicals 全氟化合物

- Perfluorobutane sulfonic acid (PFBS) 全氟丁烷磺酸
- Perfluorodecanoic acid (PFDA) 全氟癸酸
- Perfluorododecanoic acid (PFDDA) 全氟十二酸
- Perfluoroheptanoic acid (PFHpA) 全氟庚酸
- Perfluorohexane sulfonic acid (PFHS) 全氟己烷磺酸
- Perfluorononanoic acid (PFNA) 全氟壬酸
- Perfluorooctane sulfonamide (PFOSA) 全氟辛基磺酰胺
- Perfluorooctane sulfonic acid (PFOS) 全氟辛烷磺酸
- 2-(N-Ethyl-perfluorooctane sulfonamido)acetic acid (Et-PFOSA-AcOH)
- 2-(N-乙基-全氟辛烷亚磺酰氨基)乙酸
- 2-(N-Methyl-perfluorooctane sulfonamido)acetic acid (Me-PFOSA-AcOH)
- 2-(N-甲基-全氟辛烷亚磺酰氨基)乙酸
- Perfluorooctanoic acid (PFOA) 全氟辛酸
- Perfluoroundecanoic acid (PFUA) 全氟十一酸

Phthalates 邻苯二甲酸酯类

- Mono-benzyl phthalate (MBzP) 邻苯二甲酸单苄酯
- Mono-n-butyl phthalate (MnBP) 邻苯二甲酸单(正)丁酯
- Mono-(3-carboxypropyl)phthalate (MCPP) 邻苯二甲酸单-(3-羧基丙基)酯
- Mono-cyclohexyl phthalate (MCHP) 邻苯二甲酸单环己基酯
- Mono-ethyl phthalate (MEP) 邻苯二甲酸单乙酯
- Mono-(2-ethyl-5-carboxypentyl)phthalate (MECPP) 邻苯二甲酸单-(2-乙基-5-羧基戊基)酯

- Mono-(2-ethyl-5-hydroxyhexyl)phthalate (MEHHP) 邻苯二甲酸单-(2-乙基-5-羟基己基)酯
- Mono-(2-ethyl-5-oxohexyl)phthalate (MEOHP) 邻苯二甲酸单-(2-乙基-5-氧代己基)酯
- Mono-2-ethylhexyl phthalate (MEHP) 邻苯二甲酸单-(2-乙基环己基)酯
- Mono-isobutyl phthalate (MiBP) 邻苯二甲酸单异丁基酯
- Mono-isononyl phthalate (MiNP) 邻苯二甲酸单异壬基酯
- Mono-methyl phthalate (MMP) 邻苯二甲酸(单)甲酯
- Mono-n-octyl phthalate (MOP) 邻苯二甲酸单(正)辛基酯

Phytoestrogens 植物雌激素类

- Daidzein 黄豆苷原
- Enterodiol 肠二醇
- Enterolactone 肠内酯
- Equol 雌马酚
- Genistein 染料木黄酮
- O-Desmethylangolensin O-去甲基安哥拉紫檀素

Brominated Fire Retardants 溴化阻燃剂

- 2,2',4-Tribromodiphenyl ether (BDE 17) 2,2',4-三溴联苯醚
- 2,4,4'-Tribromodiphenyl ether (BDE 28) 2,4,4'-三溴联苯醚
- 2,2',4,4'-Tetrabromodiphenyl ether (BDE 47) 2,2',4,4'-四溴联苯醚
- 2,3',4,4'-Tetrabromodiphenyl ether (BDE 66) 2,3',4,4'-四溴联苯醚
- 2,2',3,4,4'-Pentabromodiphenyl ether (BDE 85) 2,2',3,4,4'-五溴联苯醚
- 2,2',4,4',5-Pentabromodiphenyl ether (BDE 99) 2,2',4,4',5-五溴联苯醚
- 2,2',4,4',6-Pentabromodiphenyl ether (BDE 100) 2,2',4,4',6-五溴联苯醚
- 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE 153) 2,2',4,4',5,5'-六溴联苯醚
- 2,2',4,4',5,6'-Hexabromodiphenyl ether (BDE 154) 2,2',4,4',5,6'-六溴联苯醚
- 2,2',3,4,4',5',6-Heptabromodiphenyl ether (BDE 183) 2,2',3,4,4',5',6-七溴联苯醚
- 2,2',4,4',5,5'-Hexabromobiphenyl (BB 153) 2,2',4,4',5,5'-六溴联苯

Polycyclic Aromatic Hydrocarbons (PAHs) 多环芳烃

- 2-Hydroxyfluorene 2-羟基芴
- 3-Hydroxyfluorene 3-羟基芴
- 9-Hydroxyfluorene 9-羟基芴
- 1-Hydroxynaphthalene (1-Naphthol) 1-羟基萘(1-萘酚)
- 2-Hydroxynaphthalene (2-Naphthol) 2-羟基萘(2-萘酚)
- 1-Hydroxyphenanthrene 1-羟基菲
- 2-Hydroxyphenanthrene 2-羟基菲
- 3-Hydroxyphenanthrene 3-羟基菲
- 4-Hydroxyphenanthrene 4-羟基菲
- 1-Hydroxypyrene 1-羟基芘

Disinfection By-Products (Trihalomethanes) 消毒副产品(三卤代甲烷)

- Bromodichloromethane 溴代二氯甲烷
- Dibromochloromethane (Chlorodibromomethane) 二溴氯甲烷(氯代二溴甲烷)
- Tribromomethane (Bromoform) 三溴甲烷(溴仿)

[作者简介] 徐甫(1988-), 男, 复旦大学公共卫生专业在读, 本科生

[*通信作者] 周志俊教授; E-mail: zjzhou@fudan.edu.cn

[作者单位] 复旦大学公共卫生学院, 上海 200032

Trichloromethane(Chloroform) 三氯甲烷(氯仿)

Volatile Organic Compounds(VOCs) 挥发性有机化合物

Benzene 苯

Chlorobenzene(Monochlorobenzene) 氯苯(一氯苯)

1,2-Dibromo-3-chloropropane(DBCP) 1,2-二溴-3-氯丙烷

Dibromomethane 二溴甲烷

1,2-Dichlorobenzene(-Dichlorobenzene) 1,2-二氯苯

1,3-Dichlorobenzene(-Dichlorobenzene) 1,3-二氯苯

1,4-Dichlorobenzene(-Dichlorobenzene) 1,4-二氯苯

1,1-Dichloroethane 1,1-二氯乙烷

1,2-Dichloroethane(Ethylene dichloride) 1,2-二氯乙烷(二氯乙烯)

1,1-Dichloroethene(Vinylidene chloride) 1,1-二氯乙烷(乙烯叉二氯)

cis-1,2-Dichloroethene 顺-1,2-二氯乙烷

trans-1,2-Dichloroethene 反-1,2-二氯乙烷

Dichloromethane(Methylene chloride) 二氯甲烷(甲叉二氯)

1,2-Dichloropropane 1,2-二氯丙烷

2,5-Dimethylfuran(DMF) 2,5-二甲基呋喃

Ethylbenzene 乙苯

Hexachloroethane 六氯乙烷

Methyl -butyl ether(MTBE) 甲基丁基醚

Nitrobenze 硝基苯

Styrene 苯乙烯

1,1,2,2-Tetrachloroethane 四氯乙烷

Tetrachloroethene(Perchloroethylene) 四氯乙烯(全氯乙烯)

Tetrachloromethane(Carbon tetrachloride) 四氯甲烷(四氯化碳)

Toluene 甲苯

1,1,1-Trichloroethane(Methyl chloroform) 三氯乙烷(甲基氯仿)

1,1,2-Trichloroethane 三氯乙烷

Trichloroethene(Trichloroethylene, TCE) 三氯乙烯

meta-and -Xylene 间二甲苯

ortho-Xylene 邻二甲苯

(收稿日期: 2009-12-28)

(编辑: 洪琪; 校对: 王晓宇)

(上接第 122 页)

[6] McPAKE B, KUMARANAYAKE L, NORMAND C. Health economics: An international perspective[M]. London: Routledge, 2002.

[7] DRUMMOND MF, STODDART GL, TORRANCE GW. Methods for the Economic Evaluation of Health Care Programmes[M]. New York: Oxford Univ. Press, 1987

[8] KLARMAN HE, FRANCIS JO, ROSENTHAL GD. Cost-effectiveness analysis applied to the treatment of chronic renal disease [J]. Med Care, 1968, 6(1): 48-54

[9] PACKER A. Applying cost-effectiveness concepts to the community health system[J]. Oper Res, 1968, 16(2): 227-253.

[10] MURRAY CJL, LOPEZ AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 [M]. Global Burden of Disease and Injury Series, Vol. 1. Cambridge, MA: Harvard Sch. Public Health/WHO/World Bank, 1996.

[11] ROBINE JM, et al. Health expectancy indicators[J]. Bulletin of the World Health Organization, 1999, 77(2): 181-185.

[12] EMMANUELLE CAMBOIS, JEAN-MARIE ROBINE, MARK D HAYWARD. Social Inequalities in Disability-Free Life Expectancy in the French Male Population, 1980-1991[J]. Demography, 2001, 38(4): 513-524.

[13] KATZ S, et al. Active life expectancy[J]. New England journal of medicine, 1983, 309(20): 1218-1224.

[14] WILKINS R, ADAMS OB. Health expectancy in Canada, late 1970s: demographic, regional and social dimensions[J]. Am J Public Health, 1983, 73(9): 1073-1080.

[15] MATHERS CD, SADANA R, SALOMON JA, et al. Healthy life expectancy in 191 countries, 1999[J]. Lancet 2001, 357(9269): 1685-1691.

[16] ANAND S, HANSON K. Disability adjusted life years: a critical review[J]. J. Health Econ, 1997, 16(6): 685-702.

[17] TORRANCE GW, BOYLE MH, HORWOOD SP. Application of multi-attribute utility theory to measure social preferences of health states[J]. Oper Res, 1982, 30(6): 1043-1069.

[18] KAPLAN RM, ANDERSON JP. A general health policy model: update and applications[J]. Health Serv Res, 1988, 23(2): 203-235.

[19] EUROQOL GROUP. EuroQol: a new facility for the measurement of health related quality of life[J]. Health Policy, 1999, 16(3): 199.

[20] ERICKSON P. Evaluation of a population-based measure of quality of life: the Health and Activity imitation Index(HALex)[J]. Quality of Life Research, 1998, 7(2): 101-114.

[21] HORNBERGER JC, REDELMEIER DA, PETERSON J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis[J]. J Clin Epidemiol, 1992, 45(5): 505-512.

[22] NORD E. Methods for quality adjustment of life years[J]. Soc Sci Med, 1992, 34(5): 559-569.

[23] GOLD MR, FRANKS P, McCOY KI, et al. Toward consistency in cost utility analyses: using national measures to create condition-specific values[J]. Med Care, 1998, 36(6): 778-92.

[24] 冯·诺伊曼, 摩根斯顿. 博弈论与经济行为[M]. 北京: 生活·读书·新知三联书店, 2004.

[25] BALABAN DJ, SAGI PC, GOLDFARB NI, et al. Weights for scoring the quality of well-being instrument among rheumatoid arthritics: a comparison to the general population weights[J]. Med Care, 1986, 24(11): 973-980.

[26] BOYLE MH, TORRANCE GW. Developing multiattribute health indexes[J]. Med Care, 1984, 22(11): 1045-1057.

[27] TORRANCE GW, FURLONG W, FEENY D, et al. Multi-attribute preference functions. Health Utilities Index[J]. Pharmacoeconomics, 1995, 7(6): 503-520.

[28] WOLFSON MC. Health-adjusted life expectancy[J]. Health Rep, 1996, 8(1): 41-46.

[29] GOLD MR, Muennig P. Measure dependent variation in burden of disease estimates: implications for policy[J]. Med Care, 2002, 40(3): 260-266.

(收稿日期: 2009-05-28)

(编辑: 丁瑾瑜; 校对: 吴德才)